Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration
Alterations in the mesenchymal-epithelial transition factor (MET) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include MET...
Saved in:
Similar Items
-
The Association Between Periodontitis and the Prevalence and Prognosis of Metabolic Syndrome
by: Li T, et al.
Published: (2025-02-01) -
METS-VF as a novel predictor of gallstones in U.S. adults: a cross-sectional analysis (NHANES 2017–2020)
by: Hui Wang, et al.
Published: (2025-07-01) -
Association between METS-VF and sarcopenia among middle-aged and older adults in China: The first longitudinal evidence from CHARLS
by: Tong Li, et al.
Published: (2025-07-01) -
Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case report
by: Jian Wang, et al.
Published: (2025-04-01) -
Correction: Evaluating the impact of metabolic syndrome on aging in US adults: a cross-sectional study from NHANES
by: Linke Li, et al.
Published: (2025-06-01)